Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial. The trial evaluated the efficacy and safety of the drug, letermovir, for prevention of cytomegalovirus infection in adult recipients of a stem cell transplant. Read more. Source: Reuters